Results 171 to 180 of about 29,154 (297)

Humanized and Charge‐Optimized CSPG4‐Specific CAR‐T Cells show Enhanced Efficacy against Head and Neck Squamous Cell Carcinoma

Advanced Science, Volume 13, Issue 35, 24 June 2026.
CSPG4 is identified as a high‐value, stemness‐associated target in HPV‐negative HNSCC. By implementing rational biophysical engineering, a humanized and charge‐optimized CAR is developed to overcome tonic signaling‐induced exhaustion. This strategy induces a profound transcriptomic shift toward a rejuvenated, stem‐like memory state, significantly ...
Xiang Xu, Shizhen Qiu, Zhitong Wang, Dan Li, Min Chen, Yinying Chu, Guangfei Li, Yi Fang, Changjiang Li, Fang Shi, Peijie He, Haitao Wu, Haopeng Wang, Jian Chen   +13 more
wiley   +1 more source

First ICOS Release: ICOS Alfa version

Delivery of the ICOS alfa release also reporting on the technical performance ...
openaire   +1 more source

Reprogramming Antitumor Immunity: NK Cell Strategies to Navigate the Immunosuppressive Tumor Microenvironment

Advanced Science, Volume 13, Issue 35, 24 June 2026.
ABSTRACT Tumor immune escape is a major barrier to durable cancer immunotherapy, as advanced malignancies create a tumor microenvironment (TME) that preferentially exhausts and disables T cell responses. While most approved cell therapies are T cell‐based, this limitation motivates the exploration of an alternative effector cell platform.
Tereza Kochs, Pranay Nath, Alice Chen, Rizwan Romee, Andreia Maia   +4 more
wiley   +1 more source

Bridging the Energy Balance Gap in Eddy-Covariance Measurements: Insights From Standardized Network Data. [PDF]

Glob Chang Biol
Nicolini G, Durden D, Di Fiore L, Florian C, Sabbatini S, Gielen B, Iserbyt A, Loubet B, Mammarella I, Mariotti A, Op de Beeck M, Slemmons C, Trotta C, Young A, Chabbi A, Feigenwinter I, Heinesch B, Kowalska N, Mauder M, Šigut L, van der Molen M, Bastos Campos F, Berveiller D, Brümmer C, Cuntz M, Domec JC, Dumont B, Fares S, Gianelle D, Jensen R, Kalalian C, Kljun N, Lange H, Limousin JM, Lundin E, Manco A, Montagnani L, Nemitz E, Peichl M, Rinne E, Roland M, Schmidt M, Simioni G, Thomas A, Vincke C, Papale D.   +45 more
europepmc   +1 more source

Reprogramming the Immune Landscape of Inflammatory Breast Cancer

Advanced Science, Volume 13, Issue 36, 29 June 2026.
Inflammatory breast cancer is the most lethal subtype of breast cancer and is characterized by an immunosuppressive tumor microenvironment (TME) driven by a complex network of immune cells and inflammatory cytokines, contributing to its aggressiveness and treatment challenges. Immune checkpoint inhibitors, either alone or in combination, show potential
Verena Martinez‐Rodriguez, Suguru Ogata, Xiaoping Wang, Naoto T. Ueno   +3 more
wiley   +1 more source

Advances in Cancer Immunotherapy for Solid Tumors

Advanced Science, Volume 13, Issue 35, 24 June 2026.
Cancer immunotherapy for solid tumors is rapidly evolving beyond classical checkpoint blockade toward more precise strategies. Emerging checkpoint targets, bispecific antibodies, antibody–drug conjugate combinations, personalized vaccines, cellular therapies, and engineered cytokines are expanding therapeutic possibilities, while biomarker‐guided ...
Shira Gabizon‐Peretz, Harriet M. Kluger   +1 more
wiley   +1 more source

Cancer Therapy-Related Cardiac Dysfunction, Risk Stratification, and Outcomes in ICOP Registry: First Data from the Arabian Middle East Region. [PDF]

Glob Heart
Farhan HA, Ali AA, Yaseen IF.
europepmc   +1 more source

Harnessing Gut Microbiota to Enhance Immunotherapy in NSCLC: From Mechanisms to Translational Applications

Cancer Medicine, Volume 15, Issue 6, June 2026.
ABSTRACT The gut microbiome has emerged as a pivotal regulator of immunotherapy efficacy in non‐small cell lung cancer (NSCLC), with mounting evidence demonstrating that microbial‐immune crosstalk significantly influences therapeutic responses. Current research reveals that commensal bacteria modulate host immunity through complex metabolic and ...
Liming Zhu, Jiayao Xu, Dong Niu, Xiangyu Zhang, Chunhui Jin   +4 more
wiley   +1 more source

Cardiac Surveillance for Anthracycline Cardiotoxicity: Clinical Yield in Low-to-Intermediate Risk Patients: MATRIX Study. [PDF]

JACC CardioOncol
Moreno-Arciniegas A, Gómez-Talavera S, Navarro-Guzman A, Galán-Arriola C, Ramos-Cillán S, Morillo D, Pardo L, Pérez-Sáenz MA, Córdoba R, Mass V, Escalera N, Fuster V, López-Fernández T, Sánchez-González J, Ibáñez B.   +14 more
europepmc   +1 more source

Annual report / ICOS. 1992

, 2013
ICOS
core